Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 5:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 1,745 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cardiovascular Risks Clear all

Conditions: Neoplasms
Interventions: Rivaroxaban, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 841 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 70
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 67 more

Conditions: Myocardial Ischemia, Rheumatic Diseases
Interventions: Caplan IVR; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 95 Years
Enrollment: 5,269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 4
States / cities: San Francisco, California • Aurora, Colorado • Baltimore, Maryland + 1 more

Conditions: High-risk Smoldering Multiple Myeloma, Smoldering Multiple Myeloma, Multiple Myeloma
Interventions: Teclistamab, Lenalidomide, Dexamethasone; Drug
Lead sponsor: Irene Ghobrial, MD; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 3
States / cities: Denver, Colorado • Boston, Massachusetts • Portland, Oregon

Conditions: Atherosclerosis
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pulmonary Embolism
Interventions: Outpatient Treatment of Pulmonary Embolism; Other
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Murray, Utah

Conditions: Acute Leukemia, Deep Vein Thrombosis, Hematopoietic and Lymphoid Cell Neoplasm, Hodgkin Lymphoma, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Thrombocytopenia
Interventions: Biospecimen Collection, Electronic Health Record Review; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Stable Coronary Artery Disease (CAD), Myocardial Infarction
Interventions: Not listed
Lead sponsor: AstraZeneca; Industry
Eligibility: 50 Years and older
Enrollment: 9,284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 34
States / cities: Huntsville, Alabama • Los Angeles, California • Santa Ana, California + 31 more

Conditions: Atrial Fibrillation New Onset
Interventions: Self-Pulse Monitoring; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 526 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Vasoplegia, Hypotension, Coronary Artery Disease, Cardiac Valve Disease
Interventions: Hydroxocobalamin, Methylene Blue, Normal saline; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Cardiovascular Risk Factor, Lipemia
Interventions: High-fat meal; Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Venous Thromboembolism
Interventions: Not listed
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 3 Months to 12 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 10
States / cities: La Jolla, California • San Diego, California • New Haven, Connecticut + 7 more

Conditions: Pulmonary Embolism
Interventions: Blood sample; Genetic
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2035
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Heart Failure
Interventions: Heart PACT Program; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: San Diego, California

Conditions: Cardiovascular Disease, Cerebrovascular Accident, Coronary Heart Disease
Interventions: Atorvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 8,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 181
States / cities: Alabaster, Alabama • Birmingham, Alabama • Hoover, Alabama + 129 more

Conditions: Nutrition, Healthy, Maternal Behavior, Health Behavior
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 89 Years
Enrollment: 115 participants
Timeline: 2023
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Atrial Fibrillation, Atrial Flutter
Interventions: Not listed
Lead sponsor: Keesler Air Force Base Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Keesler Air Force Base, Mississippi

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: CMV pp65 peptide, hTERT I540/R572Y/D988Y multipeptide vaccine, pneumococcal polyvalent vaccine, survivin Sur1M2 peptide vaccine; Biological
Lead sponsor: University of Maryland Greenebaum Cancer Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 2
States / cities: Baltimore, Maryland • Philadelphia, Pennsylvania

Conditions: Multiple Myeloma, Primary Amyloidosis
Interventions: Melphalan, Stem Cell Infusion, Questionnaires, Granulocyte-colony stimulating factor (G-CSF), Apheresis; Drug · Procedure · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 60 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cardiovascular Disease
Interventions: Controlled diet with whole grain barley, whole grain oats, or low grain diet; Other
Lead sponsor: United States Department of Agriculture (USDA); Federal
Eligibility: 25 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Beltsville, Maryland

Conditions: Metabolic Syndrome, Diabetes, Prediabetes, Hypertension
Interventions: Not listed
Lead sponsor: West Virginia School of Osteopathic Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Lewisburg, West Virginia

Conditions: Cardiovascular Risk Factor
Interventions: Choline, Placebo; Dietary Supplement
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 18 Years to 79 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Blacksburg, Virginia

Conditions: Pregnant Individuals, Aneuploidy, Down Syndrome (Trisomy 21), 22q11.2 Deletion Syndrome, Trisomy 13, Trisomy 18, Sex Chromosome Abnormalities
Interventions: Not listed
Lead sponsor: BillionToOne Inc.; Industry
Eligibility: Female only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 9
States / cities: Phoenix, Arizona • Riverside, California • West Covina, California + 5 more

Conditions: Leukemia, Lymphoma
Interventions: filgrastim, rituximab, cyclophosphamide, pentostatin; Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2005
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Coagulopathy
Interventions: Blood product transfusion based on conventional coagulation tests., Blood product transfusion based on rapid thrombelastography (r-TEG) results.; Biological
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Denver, Colorado

Search by objective public record fields.

A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants

Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

Effects of Cranberry Juice on Risk Factors for Cardiovascular Disease

Outpatient Treatment of Low-risk Pulmonary Embolism

Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study

Long-Term rIsk, Clinical manaGement and Healthcare Resource Utilization of Stable CAD in Post MI Patients

Screening for Atrial Fibrillation With Self Pulse Monitoring

Hemodynamic Effects of Methylene Blue vs Hydroxocobalamin in Patients at Risk of Vasoplegia During Cardiac Surgery

Postprandial Monocyte Maturation and Vascular Dysfunction Following High-Fat Meals - Study 1

A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot

Genetic Markers of Patients With History of Pulmonary Embolism Post Total Joint Arthroplasty

Patient Activation in High-Risk Patients With Heart Failure

A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels

Improving the Cardiovascular Health of High-Risk Families Through an Innovative Home Visitation Intervention

PREdicting Atrial Fibrillation or Flutter

Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma

Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden

Acute Heart Health Benefits of Whole Grain Barley and Oats in Healthy Men and Women

Biomarkers of Metabolic Syndrome and Prediabetes

Choline and Cardiometabolic Health

The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study Demonstrating a Circulating Fetal Cell (CFC) Based Approach to Non-invasive Fetal Risk Assessment

Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers

Comparison of Rapid Thrombelastography and Conventional Coagulation Testing for Haemostatic Resuscitation in Trauma